<DOC>
	<DOCNO>NCT01332227</DOCNO>
	<brief_summary>The purpose study determine whether HIV-1—infected patient , virologically suppress regimen 2 nucleoside reverse transcriptase inhibitor plus third agent experience safety and/or tolerability issue , maintain virologic suppression switch regimen heat-stable ritonavir boost atazanavir , 300/100 mg , daily plus raltegravir , 400 mg , twice daily .</brief_summary>
	<brief_title>Atazanavir/Ritonavir , Once Daily + Raltegravir , Twice Daily , Switch Study HIV-1—Infected Patients</brief_title>
	<detailed_description>Allocation : Randomized nonstratified Intervention model : Parallel versus comparator</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Key Inclusion Criteria Current treatment regimen 2 nucleoside reverse transcriptase inhibitor ( NRTIs ) plus third agent least 3 month immediately prior screen Virologic suppression ( HIV1 RNA &lt; 50 c/mL ) least 3 month immediately prior screen Virologic suppression ( HIV1 RNA &lt; 40 c/mL ) use Abbott m2000rt® polymerase chain reaction assay screen period Treatmentrelated safety and/or tolerability issue regimen consist 2 NRTIs plus third agent Key Exclusion Criteria History switch highly active antiretroviral therapy due virologic failure History genotypic resistance component study regimen ( atazanavir , raltegravir , tenofovir/emtricitabine ) History exposure atazanavir/ritonavir raltegravir prior enter study Experiencing safety and/or tolerability issue tenofovir/emtricitabine raltegravir Switch component HIV antiretroviral medication regimen last 3 month immediately prior screening period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>